Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia

Inclusion criteria: * Patient with age of 20 to 75 (inclusive) * Patients with fasting serum lipid panels meeting the followings: * At Visit 1 screening 100mg/dL ≤ LDL-C \< 220 mg/dL Triglyceride \< 400mg/dL However, if the patient has been treated with antihyperlipidemics for 4 consecutive weeks or longer at the time of screening, it should be 100mg/ dL ≤ LDL-C \< 160 mg/dL. * At Visit 2 screening 100mg/dL ≤ LDL-C \< 220 mg/dL Triglyceride \< 400mg/dL * Patients with CKD stage 3 to 5. * Subjects considered requiring medication by the principal investigator based on the therapeutic -guidance for hyperlipidemia of the Korean Society of Lipidology and Atherosclerosis. * Patients who understand the study procedures and signed the informed consent form. Exclusion criteria: * Patients with a hypersensitivity to HMG-CoA reductase inhibitor or any of its ingredients. * Patients who consume more than 14 units of alcohol a week, who are considered to have a history of drug overdose within 12 months of screening by the investigator, or who abuse other drugs. * Patients with the following history: * Active gallbladder disease within 12 months of screening (patients who had cholecystectomy are eligible for the study). * Pancreatitis or liver disease (AST or ALT \> 2 times the upper limit of the normal range at Visits 1 and 2). * Patients with uncontrolled diabetes mellitus (HbA1c ≥ 9.0 %). * Patients with hypotension (systolic blood pressure\< 90mmHg or diastolic blood pressure\<50mmHg). * Patients with uncontrolled hypertension: mean systolic blood pressure (SBP)\> 160mmHg or mean diastolic blood pressure (DBP) \> 100mmHg at Visit 2. * Patients with myocardial infarction or who had coronary artery bypass or angioplasty within 6 months before screening. * Patients who had stroke, transient ischemic attack (TIA), or deep vein thrombosis (DVT) within 6 months of screening. * Patients who had been treated for carotid artery disease, peripheral artery disease, or abdominal aortic aneurysm. * Patients with serious heart disease (patients with NYHA class (Attachment 4) III or IV congestive heart failure, unstable angina pectoris, or acute myocardial infarction). * Patients who were diagnosed with malignancy within 5 years or who have active tumors. * Patients with fibromyalgia, myopathy, rhadomyolysis, or sudden muscle pain, or patients who experienced adverse events during the previous treatment with statins. * Patients with mental illnesses considered by the investigator serious enough to adversely affect the patients' participation in the study. * Patients with uncontrolled primary hypothyroidism. * Patients with active peptic ulcer disease. * Patients with gastrointestinal conditions that may restrict drug absorptions, such as chronic diarrhea, inflammatory colic disease, partial ileal bypass, gastrorrhaphy, or gastric banding. * Screening CPK level \> 3 times the upper limit of the normal range. * Patients on immunosuppressives after kidney transplantation. * Patients who need to be on immunosuppressives for other reasons. * Patients who have participated in another clinical trial within the last 4 weeks of screening (except those who participated in clinical trials including observational studies that do not involve interventions such as medication). * Pregnant women, lactating women, or women of childbearing potential who do not use appropriate contraceptives. * Patients currently on dialysis. * Other patients considered ineligible by the principal investigator and investigators.